Intelligence Report · ~12 min read
Centessa Pharmaceuticals Intelligence Report
Generated from 2 signals · 2 evidence sources
Type
Company Intelligence ReportGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 75%
Evidence
9 items
Sources
6
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Centessa Pharmaceuticals maintains an active intelligence profile across Neurology, Narcolepsy, Sleep-Wake Disorders. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 75% across 2 tracked sources. Highest-priority development: FDA AP — DUPIXENT (SUPPL). Regulatory precedent. Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Centessa Pharmaceuticals.
Key Developments
Material intelligence events ranked by strategic relevance.
- regulatory
FDA AP — DUPIXENT (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA TA — ANDA219413
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — VYEPTI (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA TA — VERICIGUAT (ORIG)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — VYEPTI (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Jubilant HollisterStier General Partnership - 723537 - 05/28/2026
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 52 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA AP — DUPIXENT (SUPPL)
Moderate Confidence · 83%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA TA — ANDA219413
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — VYEPTI (SUPPL)
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA TA — VERICIGUAT (ORIG)
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — VYEPTI (SUPPL)
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceS9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Moderate Confidence · 83%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceJubilant HollisterStier General Partnership - 723537 - 05/28/2026
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments
Neurology · Sleep-Wake Disorders
- Cleminorexton Study for Narcolepsy Type 1 and Type 2 Initiated by Centessa Pharmaceuticals
Neurology · Narcolepsy